RT info:eu-repo/semantics/article
T1 Real-world evaluation of the tolerability to onabotulinum toxin A: The RETO study
A1 García Azorín, David
A1 Martínez, Blanca
A1 Gutiérrez, María
A1 Ruiz Piñero, Marina
A1 Echavarría, Ana
A1 Sierra, Álvaro
A1 Guerrero Peral, Angel Luis
K1 Botulinum toxin - Therapeutic use
K1 Toxina botulínica
K1 Neurology
K1 Migraine
K1 Migraña
K1 Chronic pain
K1 Dolor crónico
K1 Pain medicine
K1 Pain - Treatment
K1 Dolor - Tratamiento
K1 Médicaments - Effets secondaires
K1 Medicamentos - Efectos secundarios
K1 Toxicology
K1 3205.07 Neurología
K1 3214 Toxicología
AB Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical practice and to analyze if there is a relationship between tolerability to treatment administration, adverse effects’ (AEs) occurrence and clinical response. We included patients with CM that received treatment with onabotA for the first time. Tolerability to treatment was evaluated by a 0–10 numeric rating scale (0: worst possible, 10: optimal tolerability). We assessed the presence of AEs by using a standardized questionnaire. Treatment response was based on the 50 and 75% responder rate between weeks 20 and 24, compared with the baseline, according to headache diaries. We analyzed whether the tolerability was associated with a higher frequency of AEs or a higher probability of clinical response. We included 105 patients, 87.7% female, with an age of 43.9 ± 10.7 years. Mean tolerability was 7.8/10 and 7.2/10 in the first and second onabotA administration, respectively. AEs were reported by (first-second) 71.4–68.6% patients. The percentage of patients with a 50% response was 56.3%. There was no association between tolerability and AEs’ occurrence or clinical response.
PB MDPI
SN 2072-6651
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/60398
UL https://uvadoc.uva.es/handle/10324/60398
LA eng
NO Toxins, 2022, Vol. 14, Nº. 12, 850
NO Producción Científica
DS UVaDOC
RD 01-jun-2024